$JNJ 
Analyst Commentary
Credit Suisse
Strong April and May Trends in IMS Sales and Scrips Point to Upside for Q2 U.S. Pharma
Reiterates at an Outperform Rating
$161 PT
Forward Earnings Estimates 12/22   $9.95 https://t.co/L7jLXjMXES